BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/12/2026 10:07:38 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-09-04 03:28 |
|
Peer-Review Started |
|
2025-09-04 03:28 |
|
First Decision by Editorial Office Director |
|
2025-09-29 09:02 |
|
Return for Revision |
|
2025-09-29 09:28 |
|
Revised |
|
2025-10-12 04:19 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-24 02:42 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-24 07:30 |
|
Articles in Press |
|
2025-11-24 07:30 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-30 03:17 |
|
Publish the Manuscript Online |
|
2026-01-12 10:07 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhang Cheng and Ai-Min Yue |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ai-Min Yue, MD, Department of Surgical Oncology, Xinxiang Central Hospital, The Fourth Clinical College of Xinxiang Medical University, No. 56 Jinsui Avenue, Xinxiang 453000, Henan Province, China. yueaimin2025@163.com |
| Key Words |
Regorafenib; Hepatocellular carcinoma; Second-line therapy; Overall survival; Meta-analysis |
| Core Tip |
This study presents a comprehensive synthesis of current evidence regarding regorafenib’s clinical performance as a second-line treatment in patients with advanced hepatocellular carcinoma. Utilizing data from nine eligible studies, our meta-analysis provides an updated assessment of survival outcomes and tumor response metrics. Notably, regorafenib demonstrated a statistically significant improvement in overall survival compared to control groups, while objective tumor response rates did not show superiority, particularly when compared to immunotherapies such as nivolumab. Our results highlight regorafenib’s survival benefit and its role within a competitive therapeutic landscape. |
| Publish Date |
2026-01-12 10:07 |
| Citation |
Cheng Z, Yue AM. Efficacy of regorafenib in the treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis. World J Gastrointest Oncol 2026; 18(1): 113816 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i1/113816.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i1.113816 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
